日期： 2026 年 6 月 30 日, 星期二
时间： 12:00 PM – 2:00 PM
地点： Basel Marriott Hotel, Messepl. 25, 4058 Basel, Switzerland
Join internationally recognized leaders in Model-Informed Drug Development (MIDD), Piet van der Graaf and Karen R. Yeo, for an intimate and highly interactive Lunch & Learn during ISSX Basel 2026.
This invite-only session brings together a select audience of scientists and drug development leaders for a focused discussion on how mechanistic approaches and strong scientific foundations are shaping regulatory success in modern drug development.
Both speakers have played leading roles in advancing quantitative and translational sciences across industry, academia, and regulatory engagement, and have also served as Editors-in-Chief of Clinical Pharmacology & Therapeutics (CPT), helping define scientific standards and thought leadership across the field.
点击报名
Piet van der Graaf
Senior Vice President and Head of Quantitative Systems PharmacologyPiet van der Graaf, PharmD, PhD is Senior Vice President Applied BioSimulation at Certara, Professor of Systems Pharmacology at Leiden University, and Professor of Pediatrics at Cincinnati Children’s Hospital Medical Center. Previously, he was the Director of the Leiden Academic Centre for Drug Research and held leadership positions at Pfizer in Discovery Biology, DMPK and Clinical Pharmacology. Piet 于Pharmacometrics & Systems Pharmacology before becoming Editor-in-Chief of Clinical Pharmacology & Therapeutics. Piet 曾在伦敦国王学院师从诺贝尔奖获得者 Sir James Black，接受了临床医学的博士培训。He was awarded the 2024 Gary Neil Prize for Innovation in Drug Development from the American Society of Clinical Pharmacology and Therapeutics (ASCPT) and the 2021 Leadership Award from the International Society of Pharmacometrics (ISoP). Piet 是英国药理学会的当选委员，在定量药理学和药物开发领域发表了超过 250 篇同行评议的论文。
Karen Rowland Yeo, PhD
高级副总裁，客户与监管战略部Karen is Senior Vice-President, Client & Regulatory Strategy at Certara UK Limited’s Simcyp Division. Prior to this, she was the Head of PBPK Consultancy Services at Simcyp where she led a team of scientists engaged in Consultancy projects relating to the application of physiologically based pharmacokinetic (PBPK) modelling in drug development. Her work has focused on the use of PBPK models for assessment of drug-drug interactions and dosing of special populations and she is the author/co-author of more than 100 peer reviewed articles in these areas.
点击报名
